Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.56 |
| ▸ | NPC1 | O15118 | 3/20 | 0.56 |
| ▸ | RAB9A | P51151 | 3/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.56 |
| ▸ | HTT | P42858 | 2/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.56 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.56 |
| ▸ | ATM | Q13315 | 1/20 | 0.56 |
| ▸ | HPGD | P15428 | 5/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.52 |
| ▸ | NQO2 | P16083 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 6/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | CASP3 | P42574 | 1/20 | 0.51 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11796726 | 0.83 | MAPT (0.60) | MAPTALDH1A1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL11796720 | 0.83 | MAPT (0.60) | MAPTALDH1A1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL2385781 | 0.81 | MAPT (0.62) | MAPTALDH1A1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL2385787 | 0.81 | MAPT (0.62) | MAPTALDH1A1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL12251210 | 0.79 | MAPT (0.56) | MAPTALDH1A1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL13874944 | 0.79 | MAPT (0.56) | MAPTALDH1A1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL3528103 | 0.78 | HDAC6 (0.59) | MAPTALDH1A1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL3528098 | 0.78 | HDAC6 (0.59) | MAPTALDH1A1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL7384077 | 0.76 | MAPT (0.57) | MAPTALDH1A1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL12302834 | 0.76 | ALDH1A1 (0.53) | MAPTALDH1A1NPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110053935-A1 | FUSED PYRIDINES ACTIVE AS INHIBITORS OF C-MET | F. HOFFMANN-LA ROCHE AG (CH) | 2011-03-03 | — | — | US | disclosed |
| EP-1725101-A1 | 2-PYRIDINYL [7-(SUBSTITUTED-PYRIDIN-4-YL) PYRAZOLO[1,5-A] PYRIMIDIN-3-YL] METHANONES | DOV Pharmaceutical Inc. (US) | 2006-11-29 | — | — | EP | disclosed |
| US-20050277639-A1 | 2-Pyridinyl[7-(substituted-pyridin-4-yl)pyrazolo[1,5-a]pyrimidin-3-yl]methanones | DOV PHARMACEUTICAL, INC. | 2005-12-15 | — | — | US | disclosed |
| WO-2005084439-A1 | 2-PYRIDINYL[7-(SUBSTITUTED-PYRIDIN-4-YL) PYRAZOLO[1,5-A]PYRIMIDIN-3-YL]METHANONES | DOV PHARMACEUTICAL, INC. (US) | 2005-09-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050277639-A1 | 2-Pyridinyl[7-(substituted-pyridin-4-yl)pyrazolo[1,5-a]pyrimidin-3-yl]methanones | HTR1A, HTR2B, HTR4 | MAPT 178/4885ALDH1A1 724/4885NPC1 1131/4885 |
| US-20110053935-A1 | FUSED PYRIDINES ACTIVE AS INHIBITORS OF C-MET | MET, ROS1, ABL1 | MAPT 2769/4885ALDH1A1 550/4885NPC1 2302/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.